Response Genetics, Inc. (NASDAQ: RGDX)

Response Genetics, Inc. (NASDAQ: RGDX) has focused their efforts on the research and development of pharmacogenomic cancer diagnostic tests based on its patented technologies. These technologies allow the extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. RGI generates revenues through diagnostic testing services and the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens. For further information, visit the Company’s web site at www.responsegenetics.com.